AT-130


CAS No. : 211364-06-6

211364-06-6
Price and Availability of CAS No. : 211364-06-6
Size Price Stock
5mg $200 In-stock
10mg $380 In-stock
25mg $600 In-stock
50mg $1050 In-stock
100mg $1680 In-stock
200 mg Get quote
500 mg Get quote
We match the lowest price on market.

We offer a substantial discount on larger orders, please inquire via [email protected]

or Fax: (86)21-58955996

Inquiry for price and availability only. Please place your order via our email or fax.

Cat. No. : HY-100028
M.Wt: 488.33
Formula: C22H22BrN3O5
Purity: >98 %
Solubility: DMSO : 25 mg/mL (51.19 mM; Need ultrasonic)
Introduction of 211364-06-6 :

AT-130, a phenylpropenamide derivative, is a potent hepatitis B virus (HBV) replication non-nucleoside inhibitor. AT-130 inhibits the viral DNA synthesis with an EC50 of 0.13 μM. AT-130 inhibits both wt and mutant HBVs. AT-130 has anti-HBV activity in hepatoma cells[1][2][3]. In Vitro: AT-130 inhibits Wt HBV (IC50=2.4 μM), rtL180M HBV (IC50=9.8 μM), rtM204I HBV (IC50=35.6 μM)[1].
AT-130 (0.1, 1, 5, 10, 100 μM; for 7 days) causes dose-dependent inhibition of wt HBV replication in HepG2 cells transduced with HBV baculovirus. AT-130 at a concentration of 2.5 μM, reduces encapsidated HBV DNA by 50% (IC50) and at 18.5 μM by 90% (IC90)[1].
AT-130 has no toxic to either HepG2 or Huh-7 cells at concentrations of up to 250 μM[1].
AT-130 (0.005, 0.05, 0.5, 5, 50 μM) does not inhibit HBV DNA synthesis by blocking the HBV endogenous DNA polymerase reaction directly in Huh 7 or HepG2 cells. AT-130 inhibits HBV DNA replication in hepatoma cells but has no effect on viral DNA polymerase activity or core protein translation[3].
AT-130 (2.5, 18.5 μM) has no effect on total HBV RNA production but does reduce encapsidated RNA. AT-130 does not affect core protein or nucleocapsid production and the activity of the protein expression vector[3].

Your information is safe with us.